SWOT Analysis

Strength: Cluster headache is a severe form of headache that has remained underdiagnosed and underfunded. There is increased awareness regarding cluster headache owing to growing emphasis on diagnosis and treatment. Furthermore, several pharmaceutical companies are investing in research and development of novel therapies for better treatment outcomes.

Weakness: Existing treatment options for cluster headache provide only symptomatic relief and do not cure the condition. Many approved drugs are associated with tolerance and addiction. High cost of medications also limits wide accessibility of treatment.

Opportunity: Rising healthcare expenditure in developing regions provides scope for penetration of advanced treatment therapies. Further, development of new drug delivery methods such as injectables and nasal sprays can help address unmet needs in management of acute attacks.

Threats: Stringent regulations for approval of drugs delay market entry of novel therapies. Side effects associated with existing treatments discourage long-term medication adherence.

Key Takeaways

The Global Cluster Headache Market Growth is expected to witness high, exhibiting CAGR of 6.4% over the forecast period, due to increasing prevalence of cluster headache disorders worldwide. According to estimates, around 0.1% of the general population suffers from cluster headache with higher prevalence reported among men.

Regional analysis:

North America dominated the global cluster headache market in 2022 and is expected to maintain its lead over 2023-2030. This is attributed to rising disease awareness, strong healthcare infrastructure and higher adoption of advanced drugs in the region. Meanwhile, Asia Pacific cluster headache market is anticipated to emerge as the fastest growing regional market owing to growing geriatric population, improving access to diagnosis and treatment.

Key players
Key players operating in the cluster headache market are Zosano Pharma, Eli Lilly and Company, Lundbeck Seattle BioPharmaceutical, Winston Laboratories, GlaxoSmithKline plc., ElectroCore Medical LLC, Autonomic Technologies, Inc., AstraZeneca plc., Allergan plc., Bayer AG, F. Hoffmann-La Roche Ltd, Novartis AG, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, and AbbVie Inc. Major players are focusing on developing novel drug formulations to expand their product portfolios.

Explorer more information on this topic, Please visit -

https://uncoveredresearchtrends.blogspot.com/2023/12/non-invasive-neurostimulation-is.html